XML 30 R19.htm IDEA: XBRL DOCUMENT v3.26.3
Note 13 - Equity Offerings
9 Months Ended
Sep. 30, 2026
Notes to Financial Statements  
Equity [Text Block]

Note 13. Equity Offerings

 

May 2025  PIPE Financing
 
On May 12, 2025, the Company sold shares of Series B Convertible Preferred Stock and Series L common stock purchase warrants (“Series L Warrants”) in a private placement (the “May 2025 PIPE Financing”), and issued placement agent warrants to purchase 1,353 shares of common stock (the “Placement Agent Warrants”). All Series L Warrants were exercised in  February 2026 pursuant to the Letter Agreement described below, and all shares of Series B Convertible Preferred Stock were converted or repurchased during the nine months ended September 30, 2026 (see Note 14, Preferred Stock). The Placement Agent Warrants remain outstanding and are equity-classified.
 
At the Market Offering Agreement
 
On May 19, 2025, the Company entered into an At the Market Offering Agreement (“ATM Agreement”) with Ladenburg. Under the ATM Agreement, the Company may offer and sell up to $1.3 million of shares of common stock, par value $0.0001 per share, through Ladenburg. On June 13, 2025, the Company filed a prospectus supplement increasing the aggregate amount available to be sold to $3.2 million under the ATM (“Shares”). On August 7, 2025, the Company filed a prospectus supplement, which supersedes and replaces the prospectus supplement dated June 13, 2025, increasing the aggregate amount of shares available to be sold to $4.3 million. The Shares have been and will continue to be issued pursuant to the Company’s previously filed and effective Registration Statement on Form S- 3 (File No. 333- 284217), which was initially filed with the Securities and Exchange Commission on January 10, 2025 and declared effective on January 22, 2025.

 

 

The Company has no obligation to sell, and Ladenburg is not obligated to buy or sell, any of the Shares under the ATM Agreement and may at any time suspend offers under the ATM Agreement. The ATM Agreement will terminate upon the earlier of (i) the issuance and sale of all of the shares through Ladenburg on the terms and subject to the conditions set forth in the ATM Agreement or (ii) termination of the ATM Agreement as otherwise permitted thereby. The ATM Agreement may be terminated at any time by either party upon five ( 5) business days’ prior notice, or by Ladenburg at any time in certain circumstances, including the occurrence of a material adverse effect on the Company.

 

 
The Company has agreed to pay Ladenburg a commission equal to 3% of the aggregate gross proceeds from sale of its shares of common stock.
 
As of December 31, 2025, 88,785 shares of common stock had been sold under the ATM Agreement for gross proceeds of $4.0 million before deduction of commission and offering expenses of $0.3 million. During the nine months ended  September 30, 2026, no additional shares of common stock had been sold under the ATM Agreement.

 

February 2026 Private Placement

 

On February 6, 2026, the Company entered into a Securities Purchase Agreement (the “February 2026 SPA”) with certain accredited investors for a private placement financing. Pursuant to the February 2026 SPA, the Company completed the first closing and issued an aggregate of (i) 39,261 shares of the Company's common stock, par value $0.0001 per share, at a purchase price of $14.30 per share, and (ii) 1,617 shares of newly designated Series C-1 Convertible Preferred Stock. The Company collected gross proceeds of $2.2 million before deducting direct and incremental offering expenses of $0.2 million.

 

The investors agreed to purchase 1,617 shares of newly designated Series C-2 and Series C-3 Convertible Preferred Stock under additional closings for aggregate gross proceeds of $1.6 million per closing (the "Second Tranche" and "Third Tranche", respectively). Furthermore, the investors have the right, but not the obligation, to purchase up to an aggregate of $39.2 million of Series C-4 Convertible Preferred Stock in one or more closings (the "Additional Investment Right").

 

The additional closings are subject to certain closing conditions, including stockholder approval to issue shares of common stock in excess of 19.99% of the Company’s issued and outstanding shares of common stock and to effect a reverse stock split (“Stockholder Approval”). Solely with respect to the closing of the Third Tranche and any additional closings under the Additional Investment Right, the closing is subject to the declaration of the effectiveness of a Registration Statement filed for the resale of the common stock underlying the Series C-1, Series C-2, Series C-3, and Series C-4 Convertible Preferred Stock (collectively, the "Series C Convertible Preferred Stock"). The Additional Investment Right is exercisable for a period of twelve months following the later of the Stockholder Approval Date and the date the Registration Statement is first declared effective by the SEC, subject to a minimum gross proceeds threshold of $500,000 for each such additional closing. On June 23, 2026, the Company filed the Registration Statement on Form S-1 with the SEC, and on July 10, 2026, the Registration Statement was declared effective by the SEC. 

 

The Company evaluated the Series C-1 Convertible Preferred Stock as well as the additional closing rights related to the Series C-2, Series C-3, and Series C-4 Convertible Preferred Stock. The Company determined that, except as described in Note 14, Preferred Stock, with respect to certain contingent payment provisions embedded in the Series C Convertible Preferred Stock, these instruments do not require liability classification pursuant to ASC 480 and do not contain net cash settlement provisions that would preclude equity classification under ASC 815-40. Accordingly, these instruments were recorded to additional paid-in capital in the consolidated balance sheets. See Note 14, Preferred Stock, for additional information on the convertible preferred stock issued under the February 2026 SPA.

 

In connection with the February 2026 SPA, the Company also entered into a registration rights agreement with the investors requiring the Company to register for resale the shares of common stock issuable upon conversion of the Series C Convertible Preferred Stock. Failure to timely comply with certain registration obligations may require the Company to make cash payments to the investors. Upon the Registration Statement being declared effective on July 10, 2026, the Company ceased accruing additional registration delay payments.

 

On April 15, 2026, the Company obtained Stockholder Approval described above. On April 21, 2026, the Company closed the Second Tranche and issued 1,617 shares of Series C-2 Convertible Preferred Stock for aggregate gross proceeds of $1.6 million. On July 15, 2026, following the effectiveness of the Registration Statement, the Company closed the Third Tranche and issued 1,617 shares of Series C-3 Convertible Preferred Stock for aggregate gross proceeds of approximately $1.6 million. 

 

 

February 2026 Letter Agreement

 

On February 6, 2026, the Company entered into a letter agreement (the “Letter Agreement”) with the holders of the Company’s Series B Convertible Preferred Stock and Series L Warrants, which were originally issued pursuant to the Securities Purchase Agreement dated May 12, 2025. Pursuant to the Letter Agreement, the Company agreed to reduce the conversion price of the Series B Convertible Preferred Stock and the exercise price of the Series L Warrants to $17.80 per share, and the holders agreed to immediately exercise all of their Series L Warrants for cash. Following the execution of the Letter Agreement, the holders exercised 22,556 Series L Warrants to purchase 22,556 shares of common stock at the reduced exercise price of $17.80 per share, resulting in aggregate gross proceeds to the Company of approximately $0.4 million. There are no Series L Warrants outstanding as of September 30, 2026.

 

Pursuant to the Letter Agreement, the Company and the holders also agreed that the beneficial ownership limitation applicable to the Series L Warrants would be increased from 4.99% to 9.99%, effective immediately as of the date of the agreement, with the holders waiving any prior notice period requirements. Additionally, the holders agreed to certain trading volume restrictions.

 

The Company accounted for the reduction in the exercise price of the Series L Warrants as a modification of equity-classified warrants. The incremental fair value of the Series L Warrants resulting from the modification, which was measured as of the modification date using a Black-Scholes valuation model, was recognized as an equity issuance cost within additional paid-in capital in the condensed consolidated balance sheets. The Company accounted for the settlement of the Series L Warrants pursuant to the Letter Agreement as an induced exercise of equity-classified warrants. The incremental fair value of the additional consideration provided to the holders in connection with the settlement, including the incremental fair value attributable to the modified Series B Convertible Preferred Stock, was recognized as a deemed dividend within additional paid-in capital in the condensed consolidated balance sheets. See Note 14, Preferred Stock, for additional information.

 

March 2026 Private Placement

 

On March 9, 2026, the Company entered into an additional Securities Purchase Agreement (the “March 2026 SPA”) with certain accredited investors for a private placement financing. Pursuant to the March 2026 SPA, the Company completed the first closing and issued 1,853 shares of Series C-1 Convertible Preferred Stock. The Company collected gross proceeds of $1.9 million before deducting direct and incremental offering expenses of $0.1 million.

 

The investors agreed to purchase 1,853 shares of newly designated Series C- 2 and Series C- 3 Convertible Preferred Stock under additional closings (the "Second Tranche" and "Third Tranche," respectively) for aggregate gross proceeds of $1.9 million per closing. Furthermore, the investors have the right, but not the obligation, to purchase up to an aggregate of $39.2 million of Series C- 4 Convertible Preferred Stock, par value $0.0001 per share and stated value of $1,000 per share, in one or more closings (the "Additional Investment Right").

 

The closing conditions, the Additional Investment Right, the registration rights and the Company’s equity classification conclusions under the March 2026 SPA are substantially the same as those under the February 2026 SPA described above.

 

On April 15, 2026, the Company obtained Stockholder Approval described above. On April 21, 2026, the Company closed the Second Tranche and issued 1,853 shares of Series C-2 Convertible Preferred Stock for aggregate gross proceeds of $1.9 million. On July 15, 2026, following the effectiveness of the Registration Statement, the Company closed the Third Tranche and issued 1,853 shares of Series C-3 Convertible Preferred Stock for aggregate gross proceeds of approximately $1.9 million. On July 30, 2026, pursuant to the Additional Investment Right under the March 2026 SPA, the Company issued 2,821 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of approximately $2.8 million. In August 2026, pursuant to the Additional Investment Right under the March 2026 SPA, certain investors purchased an additional 4,500 shares of Series C-4 Convertible Preferred Stock for aggregate gross proceeds of $4.5 million. The Series C-4 Convertible Preferred Stock issued in August 2026 had an initial conversion price of $2.30 per share. See Note 14, Preferred Stock, for additional information regarding the terms of the Series C Convertible Preferred Stock. The Company used a portion of the net proceeds from the Series C-4 Convertible Preferred Stock issuance to fund the repurchase of all outstanding shares of Series B Convertible Preferred Stock as described in Note 14, Preferred Stock.

 

In connection with the Series C-3 Convertible Preferred Stock issuances under the February and March 2026 SPAs, the Company incurred aggregate direct offering costs of approximately $267 thousand. In connection with the Series C-4 Convertible Preferred Stock issuances under the March 2026 SPA, the Company incurred aggregate direct offering costs of approximately $528 thousand. The Company used approximately $2.2 million of the net proceeds from the Series C-3 Convertible Preferred Stock issuance to repay outstanding principal and accrued interest under the Bridge Notes and the June 2026 Note that were outstanding as of June 30, 2026, with the remaining net proceeds used to fund operations.

 

Warrants

 

The following table presents the number of common stock warrants outstanding:

 

Warrants outstanding, December 31, 2025

141,893 

Issued

— 

Exercised

(22,556)

Expired

(5,678)

Warrants outstanding, September 30, 2026

113,659 

 

As of  September 30, 2026 and December 31, 2025, all warrants outstanding are recorded in additional paid-in capital in the condensed consolidated balance sheets. The following table presents the number and type of common stock purchase warrants outstanding, their exercise price, and expiration dates as of September 30, 2026:

 

  

Warrants

         

Warrant Type

 

Outstanding

  

Exercise Price

  

Expiration Date

 

February 2022 Series B Warrants

  206  $26,600.00  

2/4/2029

 

July 2022 Series C Warrants

  149  $26,600.00  

7/22/2027

 

September 2024 Series J Warrants

  18,836  $190.00  

9/3/2029

 

September 2024 Representative Warrants

  1,130  $294.50  

8/29/2029

 

October 2024 Series K Warrants

  56,295  $133.00  

7/13/2030

 

October 2024 Placement Agent Warrants

  1,690  $206.15  

4/25/2030

 

Placement Agent Warrants May 2025

  1,353  $103.08  

6/6/2030

 

December 2025 Series M Warrants

  34,000  $15.60   3/30/2032 
   113,659         

 

 

As of September 30, 2026, the warrants issued by the Company had a weighted average exercise price of $192.46.

 

Placement Fees

 

In connection with offerings completed by the Company in 2022, (the "2022 Offerings"), the Company entered into an agreement with a placement agent that, subject to satisfaction of the requirements contained therein, called for a placement fee payable based on capital raised from certain investors for a definitive time following the expiration of the agreement. The accrued placement fee of approximat ely $1.4 million r elated to the 2022 Offerings is included in accrued expenses in the condensed consolidated balance sheets as of  September 30, 2026 and December 31, 2025. Additionally, the agreement called for the issuance of warrants with the following terms:

 

Number of shares

 

Exercise Price

 

Expiration

17 $59,375.00 

5 years

16 $33,250.00 

5 years